A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
Sign Up to like & getrecommendations! Published in 2019 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aat7838
Abstract: In the VANILLA phase 2 clinical trial, balovaptan treatment resulted in improved adaptive behaviors in adult men with autism. Modulating vasopressin in ASD The neuropeptide vasopressin has been implicated in the regulation of social behaviors… read more here.
Keywords: clinical trial; phase; men autism; trial ... See more keywords